Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03451994 · ClinicalTrials.gov registry record
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
A clinical trial, sponsored by Mebo Research.
- Completed
- Registry status
- 23
- Enrollment target
NCT03451994: Completed study, sponsored by Mebo Research.
NCT03451994 is a clinical trial that has completed, run by Mebo Research. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03451994 has completed, sponsored by Mebo Research.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
The purpose of this secondary analysis is to identify breath signatures associated with idiopathic malodor conditions.
Primary Outcome
Expired air sample drawn principally from alveolar breath is analyzed by gas chromatography-mass spectrometry. Chromatograms are searched against the NIST library. The response for each analyte is normalized by using internal standards containing 1-bromo-4-fluoro-benzene.
Interventions
- OTHER Breath test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-10-01 |
| Est. Completion | 2020-10-11 |
What the finished NCT03451994 record still lists
NCT03451994 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Breath test is the first listed.
NCT03451994 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03451994 about?
NCT03451994 is a clinical study titled "Exploratory Study of Volatile Organic Compounds in Alveolar Breath". The purpose of this secondary analysis is to identify breath signatures associated with idiopathic malodor conditions.
What is the current status of trial NCT03451994?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2011-10-01. Estimated completion is 2020-10-11.
What interventions are being tested in trial NCT03451994?
The interventions under investigation include: Breath test (OTHER).
Who is sponsoring clinical trial NCT03451994?
This trial is sponsored by Mebo Research, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI